Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01734928
Title Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Celgene Corporation
Indications

multiple myeloma

Therapies

Pomalidomide

Bortezomib + Dexamethasone

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | AUT


No variant requirements are available.